In 2011, a new drug named Xarelto was approved for the purposes of preventing blood clots and strokes. Manufactured by Bayer AG and Janssen Pharmaceuticals, the drug targeted patients who suffer from Pulmonary Embolism (PE), Atrial Fibrillation (Afib), and Deep Vein Thrombosis (DVT). Since its release, the drug has done […]